Singapore startups are tapping China’s vast patient pool, hospital networks and manufacturing capabilities, but they must also navigate its evolving regulatory landscape. Singapore biomedical startups are expanding into China to accelerate the development of new treatments for cancer and diabetes. A*STAR spin-offs Lion TCR and BetaLife are tapping China's vast.